---
layout: post
title: "Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population."
date:
author: "Habakuk Hain"
categories: transmission
tags: ["Down syndrome", "Alzheimer biomarkers", "amyloid staging"]
image:
rating: 8
paper_title: "Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population."
paper_author: "Russell"
paper_journal: "Current opinion in neurology"
paper_year: "2026"
paper_doi: "https://doi.org/10.1097/WCO.0000000000001461"
paper_et_al: true
summary: "This review demonstrates how Down syndrome provides a unique genetic model for understanding Alzheimer's disease, with near-universal AD neuropathology by age 40 and predictable biomarker trajectories that mirror sporadic AD. The genetically determined nature of DS-AD enables precise staging and early intervention strategies that can inform broader AD therapeutic approaches."
author_context: "Alzheimer's Therapeutic Research Institute, USCâ€”leading AD research center with expertise in clinical trials and biomarker development"
---

**Problem**: The need for better understanding of AD natural history and biomarker evolution to enable earlier detection and intervention strategies.

**Result**: DS-AD demonstrates predictable trajectories of amyloid, tau, and neurodegeneration decades before dementia onset, with biomarker patterns that closely align with sporadic AD but follow a more compressed timeline.

**Open Questions**: Whether therapeutic interventions based on DS-AD insights will successfully translate to sporadic AD populations remains to be proven in ongoing clinical trials.
